Inclusion Criteria:

- Histologically or cytologically confirmed sarcoma of soft tissue or bone

- Metastatic and/or locally advanced or locally recurrent disease by physical exam
or imaging

- Measurable disease by RECIST criteria

- Measurable disease ('target' lesion) is defined as at least one lesion that can
be accurately measured in at least one dimension (longest diameter to be
recorded) as ≥ 10 mm by CT scan (CT scan slice thickness ≤ 5 mm) or calipers by
clinical exam (lesions that cannot be accurately measured with calipers should
be recorded as non-measurable) OR as ≥ 20 mm by chest x-ray

- Must have received and failed 1-3 prior chemotherapy regimens for
recurrent/metastatic disease

- Patients at MSKCC must consent to tumor biopsies before treatment and after the
second week of therapy

- Patients who do not have accessible tumor for biopsy may be allowed at the
discretion of the principal investigator

- Confirmation of IGF1R status in pre-existing tumor specimens by IHC

- Brain metastases allowed provided they were previously treated with definitive
surgery or radiotherapy and have been clinically stable for 3 months following the
procedure with no neurological signs or symptoms and no requirement for systemic
glucocorticoids

- ECOG performance status 0 or 1

- ANC ≥ 1.5 times 10^9/L

- Platelet count ≥ 100 times 10^9/L

- Total bilirubin ≤ 1.5 times upper limit of normal (ULN) (except for patients with
known Gilbert syndrome)

- AST and ALT ≤ 2.5 times ULN

- Serum creatinine ≤ 1.5 times ULN

- Serum glucose ≤ 120 mg/dL (nonfasting or fasting)

- No hyperglycemia, defined as fasting serum glucose > 120 mg/dL

- Fasting total cholesterol ≤ 300 mg/dL

- Fasting triglycerides ≤ 2.5 times ULN

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No current evidence of another malignancy

- No history of allergic reactions attributed to compounds of similar chemical or
biologic composition to temsirolimus, cixutumumab, or other agents used in the study

- No concurrent uncontrolled illness including, but not limited to, the following:

- Known ongoing or active infection, including HIV or active hepatitis B or C
infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia (e.g., atrial fibrillation or ventricular dysrhythmias [other
than premature ventricular contractions])

- Psychiatric illness/social situation that would limit compliance with study
requirements

- No other concurrent anticancer agents or therapies

- Recovered from prior therapy

- At least 4 weeks since prior systemic therapy (including tyrosine kinase inhibitors)
(6 weeks for carmustine or mitomycin C)

- More than 4 weeks since prior major surgery and recovered

- Surgical changes that are not expected to improve (e.g., removal of muscle
tissue) allowed

- More than 4 weeks since prior glucocorticoid therapy administered for > 5 days

- Replacement glucocorticoids for pre-existing deficiency (e.g., Addison disease)
allowed

- No prior IGFR1 inhibitors

- No prior mTOR inhibitors (e.g., sirolimus, everolimus, deforolimus, or temsirolimus)

- No concurrent oral anti-diabetic or insulin therapy

- No concurrent prophylactic hematopoietic colony-stimulating factors

- No other concurrent investigational agents